Emerging technologies impacting cancer care: how Dune Medical is helping surgeons identify additional cancer in the operating room

MarginProbe recognized as a noteworthy medical device for helping reduce positive margins for lumpectomy surgeries by Tim Clay during an interview for News Medical Life Sciences.

Dune Medical develops, manufactures, and commercializes innovative products that improve the effectiveness and outcome of cancer surgery by providing real-time tissue characterization systems to guide surgical and diagnostic decisions. Our cardinal medical device is the MarginProbe: an FDA-approved breakthrough in lumpectomy surgery that helps surgeons by providing real time information to determine whether additional tissue should be taken, or to complete the lumpectomy procedure, and close the incision.

“We put unique clinically actionable information into the hands of surgeons while in the OR to help them make the best possible decisions for patient care,” says Lori Chmura, CEO of Dune Medical Devices. “Improving the standard of care around cancer surgery is what we strive for each and every day.”

In a recent interview with Tim Clay, Associate Director for Cambridge Consultants conducted by April Cashin-Garbutt for News Medical Life Sciences, MarginProbe was highlighted as an emerging technology in the field of cancer treatment.tim-clay

When asked what he believes the future holds for emerging technologies in cancer care, he said “We must think about what non-optical technologies are out there,” and that is where MarginProbe steps in.

“One is a product called MarginProbe,” says Clay. “This is being developed by Dune Medical in the US and is a way of being able to define cancer or normal tissues by means of an electromagnetic measurement called fringe field sensing. Essentially, it is a probe that looks at the impedance changes between cancerous tissue and normal tissue. It has been used in breast cancer patients and has been shown to reduce the re-operation rate, they have been shown to be reduced by 56%, which is a huge saving to the surgical world.”

You can read the full interview here.

If you would like to learn more about RF spectroscopy’s capability to reduce re-excisions for breast cancer patients or what the future of our technology holds for biopsy in breast cancer and other indications, contact info@dunemedical.com to hear more about the emerging technologies produced by Dune Medical.